Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | KRAS | P01116 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.38 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 2/20 | 0.38 |
| ▸ | LITAF | Q99732 | 2/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4419521 | 0.93 | USP30 (0.41) | USP30MEN1KMT2ATP53CNR1 | |
| SCHEMBL4408792 | 0.89 | TP53 (0.46) | USP30KMT2ATP53KRASSMARCA2 | |
| SCHEMBL4409882 | 0.88 | FPR2 (0.43) | USP30TP53KRASSMARCA2SMARCA4 | |
| SCHEMBL4408213 | 0.86 | USP30 (0.43) | USP30TP53SMARCA2SMARCA4PBRM1 | |
| SCHEMBL4410166 | 0.85 | USP30 (0.51) | USP30SMARCA2SMARCA4PBRM1 | |
| SCHEMBL23512857 | 0.84 | USP30 (0.39) | USP30MEN1KMT2ATP53CNR1 | |
| SCHEMBL29693184 | 0.84 | USP30 (0.39) | USP30MEN1KMT2ATP53CNR1 | |
| SCHEMBL26041621 | 0.84 | USP30 (0.39) | USP30MEN1KMT2ATP53CNR1 | |
| SCHEMBL23512534 | 0.84 | USP30 (0.39) | USP30MEN1KMT2ATP53CNR1 | |
| SCHEMBL4411908 | 0.84 | TP53 (0.46) | USP30KMT2ATP53SMARCA2SMARCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | HTR2C, HTR2A, HTR5A | USP30 4369/4885MEN1 1646/4885KMT2A 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.